Oncternal Therapeutics, Inc. — Revenue by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/66757c5f-bb46-4760-86e2-e06130daaf6f/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2023 | $785.0k | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-027984 |
| FY 2022 | $1.5M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-007062 |
| FY 2021 | $4.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-009702 |
| FY 2020 | $3.4M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-012588 |
| FY 2019 | $2.4M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-011213 |
| FY 2018 | $2.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-20-011213 |
| FY 2011 | $6.7M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-093770 |
| FY 2010 | $60.6M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-093770 |
| FY 2009 | $3.3M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-093770 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Oncternal Therapeutics, Inc. — all facts · Net Income · Operating Income